Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been given a consensus rating of “Moderate Buy” by the nine analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $21.1250.

A number of research firms have issued reports on TLX. Citigroup boosted their price objective on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a report on Tuesday, February 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, April 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, April 13th. Finally, Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th.

Telix Pharmaceuticals Trading Down 1.0%

NASDAQ TLX opened at $9.43 on Tuesday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $18.49. The firm has a 50-day moving average price of $10.01 and a two-hundred day moving average price of $8.73.

Insider Transactions at Telix Pharmaceuticals

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch acquired 33,435 shares of the business’s stock in a transaction on Wednesday, April 29th. The stock was purchased at an average price of $14.87 per share, with a total value of $497,178.45. Following the acquisition, the chief executive officer directly owned 20,742,935 shares of the company’s stock, valued at approximately $308,447,443.45. This trade represents a 0.16% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Lazard Asset Management LLC raised its position in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares in the last quarter. Portland Investment Counsel Inc. raised its position in shares of Telix Pharmaceuticals by 108.0% in the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock valued at $2,063,000 after buying an additional 138,200 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Telix Pharmaceuticals in the 3rd quarter valued at approximately $1,883,000. Private Advisor Group LLC raised its position in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at approximately $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.